Cefpodoxime proxetil: A review of its use in the management of bacterial infections in paediatric patients

Paediatric Drugs

Volumn 3, Issue 2, 2001, Pages 137-158

  Fulton, Bret ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFACLOR; CEFPODOXIME PROXETIL; CEPHALOSPORIN DERIVATIVE; PENICILLIN V;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; CHILD CARE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HUMAN; INTESTINE FLORA; LOWER RESPIRATORY TRACT INFECTION; OTITIS MEDIA; PHARYNGITIS; PRIORITY JOURNAL; RASH; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; TONSILLITIS;

EID: 0035091881     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103020-00006     Document Type: Review

References (122)

1. Cefpodoxime proxetil: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential
2. In vitro activity of cefpodoxime in comparison with other oral β-lactam antibiotics
3. Antibacterial activity of cefpodoxime in vitro
4. Streptococcus pneumoniae in the USA: In vitro susceptibility and pharmacodynamic analysis
5. Activity of cefpodoxime, an oral 3rd generation cephalosporin
6. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers
7. Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Morarella catarrhalis
8. Comparative in vitro activity of cefpodoxime proxetil and other cephalosporin against Gram-positive bacterias [abstract]
9. An-vitro-aktivität von cefpodoxim im vergleich zu anderen oralen antibiotika
10. In vitro activity of cefpodoxime proxetil: An Australian multi-centre study
11. In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae
12. Microbiological evaluation of cefpodoxime proxetil
13. In vitro activity of cefpodoxime and ten other cephalosporins against Gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including β-lactamase producers
14. In vitro activity of cefpodoxime, a new oral cephalosporin
15. The in-vitro activity of cefpodoxime: A comparison with other oral cephalosporins
16. Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: Implications for treatment of community-acquired lower respiratory tract infections
17. Efficacy of beta-lactam antibiotics: Integration of pharmacokinetics and pharmacodynamics
18. Clinical pharmacokinetics of oral cephalosporins
19. Pharmacokinetic and pharmacodynamic considerations in antibiotic selection with particular attention to oral cephalosporins
20. Pharmacodynamic activity of five oral cephalosporins against Haemophilus influenzae
21. Serum bactericidal activity against Moraxella catarrhalis and Streptococcus pneumoniae after administration of four oral cephalosporins in healthy volunteers
22. A review of the pharmacokinetics of cefpodoxime proxetil
23. Clinical trials of cefpodoxime proxetil suspension in paediatrics
24. Single dose pharmacokinetics of cefpodoxime proxetil in infants and children
25. Cefpodoxime pharmacokinetics in children: Effect of food
26. Clinical and pharmacokinetic evaluation of cefpodoxime proxetil in children
27. Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field
28. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses
29. Pharmacokinetic, bacteriological and clinical evaluation of cefpodoxime proxetil in pediatrics
30. Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field
31. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil
32. Effect of timing of food on absorption of cefpodoxime proxetil
33. Overall clinical evaluation of cefpodoxime proxetil against infections in pediatric fields
34. The bioavailability of cefpodoxime proxetil tablets relative to an oral solution
35. 2 receptor antagonist
36. Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil
37. Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine
38. Effects of nifedipine and diltiazem on pharmacokinetics of cefpodoxime following its oral administration
39. Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil
40. Penetration of cefpodoxime proxetil in lung parenchyma and epithehal lining fluid of noninfected patients
41. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies
42. Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil
43. Cefpodoxime proxetil concentrations in head and neck tissues
44. Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil
45. Concentrations of cefpodoxime in plasma, adenoid, and tonsillar tissue after repeated administrations of cefpodoxime proxetil in children
46. Penetration of cefpodoxime into middle ear fluid in pediatric patients with acute otitis media
47. Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil
48. Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers
49. Human skin disposition of cefpodoxime after oral administration of its proxetil ester
50. Periodontal tissue distribution of cefpodoxime proxetil and efficacy in acute odontogenic infections
51. Cerebrospinal fluid pharmacokinetics of cefpodoxime proxetil in piglets
52. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function
53. Disposition of cefpodoxime proxetil in hemodialysis patients
54. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis
55. Therapeutic considerations for management of otitis media, sinusitis, and tonsillophasyngitis
56. Management of acute otitis media in the 1990s: The decade of resistant pneumococcus
57. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The 'Pollyanna phenomenon'
58. Randomized trial comparing 5-day cefpodoxime proxetil and 8-day amoxicillin-clavulanate treatment of acute otitis media in children
59. Twice daily cefpodoxime proxetil compared with thrice daily amoxicillin/clavulanic acid for treatment of acute otitis media in children
60. Efficacy and safety of cefpodoxime proxetil (8 mg/kg/day) for 5 days vs. amoxicillin/clavulanic acid (40 mg/kd/day) for 8 days in the treatment of acute otitis media in children
61. Cefpodoxime proxetil compared with amoxicillin-clavulanate for the treatment of otitis media
62. Comparison of cefpodoxime proxetil and cefixime in the treatment of acute otitis media in infants and children
63. Cefpodoxime proxetil vs. cefixime for painful febrile acute otitis media in children
64. Cefpodoxime proxetil suspension compared with cefaclor suspension for treatment of acute otitis media in paediatric patients
65. Comparison of once daily cefpodoxime proxetil suspension and thrice daily cefaclor suspension in the treatment of acute otitis media in children
66. Treatment of acute otitis media (AOM) in pediatric patients: Comparison of cefuroxime axetil (CAE) with cefpodoxime proxetil (CPD)
67. Cefpodoxime proxetil vs co-amoxiclav in the treatment of acute infections of the ear, nose and throat in children-a multicentre randomized study
68. Five vs. ten days of antibiotic therapy for acute otitis media in young children
69. Multicenter open-label trial of cefodoxime proxetil in febrile and painful acute otitis media in infants and children
70. The clinical efficacy of Banan dry syrup on children with otorhinolaryngological infections
71. Effect of CPDX-PR on pediatric infections
72. Comparative study of the efficacy of cefpodoxime proxetil (CPDX-PR) dry syrup at two doses in pediatric otorhinolaryngology
73. Efficacy and safety of cefpodoxime proxetil (Orelox® Junior) in children with RTI
74. Cefpodoxime proxetil vs. penicillin V in pediatric streptococcal pharyngitis/tonsillitis
75. Cefpodoxime proxetil versus penicillin V in the treatment of streptococcal pharyngitis in children
76. Effective short-course treatment of acute group A β-hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children
77. Five versus ten days treatment of streptococcal pharyngotonsillitis: A randomized controlled trial comparing cefpodoxime proxetil and phenoxymethyl penicillin
78. A multi-institutional study on clinical effectiveness of cefpodoxime proxetil dry syrup in childhood infections
79. The clinical study of cefpodoxime proxetil dry syrup preparation in the pediatric field
80. Evaluation of cefpodoxime proxetil dry syrup in pediatric patients with various infections
81. Treatment of community-acquired pneumonia in paediatric patients: Comparison of cefuroxime axetil with cefpodoxime proxetil
82. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood
83. Evaluation of cefpodoxime proxetil in the patient with various pediatric infections
84. Comparative effectiveness and safety of cefpodoxime proxetil versus cefuroxime axetil for the treatment of skin and soft-tissue infections
85. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections
86. Microbiological and clinical studies on cefpodoxime proxetil for bacterial skin and soft tissue infections in pediatric patients
87. Microbiological and clinical studies on cefpodoxime proxetil in pediatric patients with bacterial skin and soft tissue infections
88. Clinical evaluation of cefpodoxime proxetil (Banan) dry syrup in patients with bactedal skin infection in children
89. Microbiological and clinical studies on cefpodoxime proxetil in bacterial skin and soft tissue infections
90. Clinical evaluation of cefpodoxime proxetil in various superficial infectious skin diseases
91. Clinical study of cefpodoxime proxetil dry syrup for skin and soft tissue infections in the field of pediatrics
92. Bacteriological and clinical evaluation of cefpodoxime proxetil (Banan registered dry syrup) against impetigo contagiosa
93. Cefpodoxime proxetil in the treatment of skin and soft tissue infections
94. Clinical evaluation of cefpodoxime proxetil dry syrup in pediatric cutaneous bacterial infection
95. The overall safety of cefpodoxime proxetil (CPD) suspension in paediatric clinical studies
96. The relationship between an increase in β-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances
97. Impact of cefpodoxime proxetil and amoxicillin on the normal oral and intestinal microflora
98. Effect of cefpodoxime proxetil and amoxicillin on the normal oropharyngeal and intestinal microflora
99. Presence of Clostridium difficile and antibiotic and β-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo
100. Changes in fecal flora and comparative multiple-dose pharmacokinetics of ceftibuten, cefpodoxime proxetil and amoxycillin/clavulanate
101. The influence of cefpodoxime proxetil on the intestinal bacterial flora
102. Beeinflussung der körpereigenen flora durch verschiedene oral verabreichte antibiotika und chemotherapeutika
103. Penicillin- and cephalosporin-resistant Streptococcus pneumoniae: Emerging treatment for an emerging problem
104. Consensus: Management of infections in children caused by Streptococcus pneumoniae with decreased susceptibility to penicillin
105. Evaluation of amoxicillin clavulanate twice daily versus thrice daily in the treatment of otitis media in children
106. Empiric antibiotic selection criteria for respiratory infections in pediatric practice
107. A double-blind taste comparison of pediatric antibiotic suspensions
108. Enhancing children's satisfaction with antibiotic therapy: A taste study of several antibiotic suspensions
109. Clinical efficacy of antimicrobial drugs for acute otitis media: Metaanalysis of 5400 children from thirty-three randomized trials
110. Are antibiotics indicated as initial treatment for children with acute otitis media? A meta-analysis
111. Antibiotic treatment of acute otitis media in children under two years of age: Evidence based?
112. Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years
113. Acute otitis media
114. Antimicrobial therapy of acute otitis media: Review of treatment recommendations
115. Acute otitis media: Management and surveillance in an era of pneumococcal resistance - A report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group
116. A pharmacoeconomic comparison of amoxicillin/clavulanate potassium and cefpodoxime proxetil in the treatment of acute otitis media
117. Treatment of acute otitis media with a shortened course of antibiotics: A meta-analysis
118. Duration of therapy for acute otitis media